Back
Flashcards: NS5A inhibitors
Ledipasvir/sofosbuvir
Ledipasvir/sofosbuvir (trade name Harvoni) is a two-drug combination for the treatment of hepatitis C.
Ledipasvir
Ledipasvir (formerly GS-5885) is a drug for the treatment of hepatitis C that was developed by Gilead Sciences.
Deleobuvir
Deleobuvir (formerly BI 207127) was an experimental drug for the treatment of hepatitis C.
Ombitasvir
Ombitasvir is an antiviral drug for the treatment of hepatitis C virus (HCV) infection.
Velpatasvir
Velpatasvir is an inhibitor of NS5A used together with sofosbuvir in the treatment of hepatitis C infection of all six major genotypes.
Velpatasvir/sofosbuvir
Velpatasvir/sofosbuvir (trade name Epclusa) is a two-drug combination for the treatment of hepatitis C.
Daclatasvir
Daclatasvir (trade name Daklinza) is a drug for the treatment of hepatitis C (HCV).
Ravidasvir
Ravidasvir (PPI-668) is an investigational NS5A inhibitor in clinical trials for chronic hepatitis C genotype 4.
Odalasvir
Odalasvir (INN, previously known as ACH-3102) is an investigational new drug in development for the treatment of hepatitis C.
Sofosbuvir/daclatasvir
Daclatasvir/sofosbuvir (trade name Darvoni) is a two-drug combination for the treatment of hepatitis C.
Samatasvir
Samatasvir (IDX-719) is an experimental drug for the treatment of hepatitis C.